nodes	percent_of_prediction	percent_of_DWPC	metapath
Diclofenac—PTGS2—muscle cancer	0.254	1	CbGaD
Diclofenac—ABCC1—Dactinomycin—muscle cancer	0.0541	0.0971	CbGbCtD
Diclofenac—SLCO1C1—Methotrexate—muscle cancer	0.0523	0.0937	CbGbCtD
Diclofenac—CYP1A1—Dacarbazine—muscle cancer	0.0386	0.0691	CbGbCtD
Diclofenac—UGT1A1—Etoposide—muscle cancer	0.0372	0.0666	CbGbCtD
Diclofenac—ABCC1—Vincristine—muscle cancer	0.0333	0.0598	CbGbCtD
Diclofenac—ABCC1—Etoposide—muscle cancer	0.0305	0.0548	CbGbCtD
Diclofenac—CYP2E1—Dacarbazine—muscle cancer	0.0298	0.0534	CbGbCtD
Diclofenac—SLC22A11—Methotrexate—muscle cancer	0.027	0.0484	CbGbCtD
Diclofenac—ABCC4—Methotrexate—muscle cancer	0.0251	0.045	CbGbCtD
Diclofenac—PTGS2—Etoposide—muscle cancer	0.0223	0.0401	CbGbCtD
Diclofenac—ABCC1—Doxorubicin—muscle cancer	0.0208	0.0374	CbGbCtD
Diclofenac—ABCC1—Methotrexate—muscle cancer	0.0202	0.0362	CbGbCtD
Diclofenac—PTGS1—Etoposide—muscle cancer	0.0189	0.0338	CbGbCtD
Diclofenac—CYP1A2—Dacarbazine—muscle cancer	0.0172	0.0309	CbGbCtD
Diclofenac—SLC22A8—Methotrexate—muscle cancer	0.0157	0.0281	CbGbCtD
Diclofenac—CYP2E1—Etoposide—muscle cancer	0.0146	0.0261	CbGbCtD
Diclofenac—ABCB1—Dactinomycin—muscle cancer	0.0131	0.0234	CbGbCtD
Diclofenac—SLC22A6—Methotrexate—muscle cancer	0.0109	0.0196	CbGbCtD
Diclofenac—CYP2C8—Etoposide—muscle cancer	0.0109	0.0195	CbGbCtD
Diclofenac—CYP2B6—Doxorubicin—muscle cancer	0.0098	0.0176	CbGbCtD
Diclofenac—ALB—Methotrexate—muscle cancer	0.00931	0.0167	CbGbCtD
Diclofenac—CYP1A2—Etoposide—muscle cancer	0.00843	0.0151	CbGbCtD
Diclofenac—ABCB1—Vincristine—muscle cancer	0.00804	0.0144	CbGbCtD
Diclofenac—ABCB1—Etoposide—muscle cancer	0.00737	0.0132	CbGbCtD
Diclofenac—ABCB1—Doxorubicin—muscle cancer	0.00503	0.00901	CbGbCtD
Diclofenac—ABCB1—Methotrexate—muscle cancer	0.00487	0.00873	CbGbCtD
Diclofenac—CYP3A4—Vincristine—muscle cancer	0.00482	0.00864	CbGbCtD
Diclofenac—CYP3A4—Etoposide—muscle cancer	0.00442	0.00792	CbGbCtD
Diclofenac—CYP3A4—Doxorubicin—muscle cancer	0.00301	0.0054	CbGbCtD
Diclofenac—CXCR1—bone marrow—muscle cancer	0.00216	0.0488	CbGeAlD
Diclofenac—PTGS2—hindlimb—muscle cancer	0.00125	0.0282	CbGeAlD
Diclofenac—ASIC1—head—muscle cancer	0.00114	0.0257	CbGeAlD
Diclofenac—ASIC1—testis—muscle cancer	0.0011	0.0248	CbGeAlD
Diclofenac—PTGS2—appendage—muscle cancer	0.00107	0.0242	CbGeAlD
Diclofenac—PLA2G2A—smooth muscle tissue—muscle cancer	0.00106	0.024	CbGeAlD
Diclofenac—CXCL8—smooth muscle tissue—muscle cancer	0.00105	0.0238	CbGeAlD
Diclofenac—PLA2G2A—renal system—muscle cancer	0.00102	0.0231	CbGeAlD
Diclofenac—TTR—embryo—muscle cancer	0.00102	0.0231	CbGeAlD
Diclofenac—PLA2G2A—cardiac atrium—muscle cancer	0.000917	0.0207	CbGeAlD
Diclofenac—Bromfenac—PTGS2—muscle cancer	0.000909	0.261	CrCbGaD
Diclofenac—KCNQ3—head—muscle cancer	0.000904	0.0204	CbGeAlD
Diclofenac—SLCO1C1—renal system—muscle cancer	0.000865	0.0195	CbGeAlD
Diclofenac—UGT2B7—renal system—muscle cancer	0.000862	0.0195	CbGeAlD
Diclofenac—SLC22A11—renal system—muscle cancer	0.00084	0.019	CbGeAlD
Diclofenac—KCNQ2—head—muscle cancer	0.000832	0.0188	CbGeAlD
Diclofenac—KCNQ2—testis—muscle cancer	0.000804	0.0182	CbGeAlD
Diclofenac—PLA2G2A—tendon—muscle cancer	0.000799	0.0181	CbGeAlD
Diclofenac—SCN4A—renal system—muscle cancer	0.000795	0.018	CbGeAlD
Diclofenac—Lumiracoxib—PTGS2—muscle cancer	0.000773	0.222	CrCbGaD
Diclofenac—TTR—renal system—muscle cancer	0.000773	0.0175	CbGeAlD
Diclofenac—CXCL8—bone marrow—muscle cancer	0.000766	0.0173	CbGeAlD
Diclofenac—Nepafenac—PTGS2—muscle cancer	0.000735	0.211	CrCbGaD
Diclofenac—CXCL8—vagina—muscle cancer	0.000734	0.0166	CbGeAlD
Diclofenac—UGT1A1—renal system—muscle cancer	0.000733	0.0166	CbGeAlD
Diclofenac—ALOX5—smooth muscle tissue—muscle cancer	0.000728	0.0165	CbGeAlD
Diclofenac—PLA2G2A—head—muscle cancer	0.000685	0.0155	CbGeAlD
Diclofenac—CYP2C18—vagina—muscle cancer	0.000677	0.0153	CbGeAlD
Diclofenac—PLA2G2A—testis—muscle cancer	0.000662	0.015	CbGeAlD
Diclofenac—CXCL8—testis—muscle cancer	0.000655	0.0148	CbGeAlD
Diclofenac—SCN4A—tendon—muscle cancer	0.00062	0.014	CbGeAlD
Diclofenac—Meclofenamic acid—PTGS2—muscle cancer	0.000602	0.173	CrCbGaD
Diclofenac—TTR—bone marrow—muscle cancer	0.000585	0.0132	CbGeAlD
Diclofenac—SLCO1C1—head—muscle cancer	0.000579	0.0131	CbGeAlD
Diclofenac—SLCO1C1—testis—muscle cancer	0.000559	0.0126	CbGeAlD
Diclofenac—UGT2B7—testis—muscle cancer	0.000557	0.0126	CbGeAlD
Diclofenac—SCN4A—head—muscle cancer	0.000532	0.012	CbGeAlD
Diclofenac—ALOX5—bone marrow—muscle cancer	0.00053	0.012	CbGeAlD
Diclofenac—TTR—head—muscle cancer	0.000517	0.0117	CbGeAlD
Diclofenac—SCN4A—testis—muscle cancer	0.000514	0.0116	CbGeAlD
Diclofenac—TTR—testis—muscle cancer	0.0005	0.0113	CbGeAlD
Diclofenac—ABCC4—renal system—muscle cancer	0.000478	0.0108	CbGeAlD
Diclofenac—SLC22A8—renal system—muscle cancer	0.000474	0.0107	CbGeAlD
Diclofenac—ALOX5—head—muscle cancer	0.000469	0.0106	CbGeAlD
Diclofenac—Mefenamic acid—PTGS2—muscle cancer	0.000468	0.134	CrCbGaD
Diclofenac—ALOX5—testis—muscle cancer	0.000453	0.0102	CbGeAlD
Diclofenac—ABCC4—tendon—muscle cancer	0.000373	0.00843	CbGeAlD
Diclofenac—ABCC1—cardiac atrium—muscle cancer	0.000365	0.00824	CbGeAlD
Diclofenac—ABCC4—bone marrow—muscle cancer	0.000361	0.00816	CbGeAlD
Diclofenac—PTGS2—embryo—muscle cancer	0.000355	0.00803	CbGeAlD
Diclofenac—CYP2C8—renal system—muscle cancer	0.000347	0.00784	CbGeAlD
Diclofenac—CYP1A2—renal system—muscle cancer	0.000325	0.00733	CbGeAlD
Diclofenac—CYP1A1—renal system—muscle cancer	0.00032	0.00724	CbGeAlD
Diclofenac—ABCC4—head—muscle cancer	0.00032	0.00722	CbGeAlD
Diclofenac—ALB—testis—muscle cancer	0.000319	0.00721	CbGeAlD
Diclofenac—ABCC1—tendon—muscle cancer	0.000318	0.00719	CbGeAlD
Diclofenac—SLC22A8—head—muscle cancer	0.000317	0.00717	CbGeAlD
Diclofenac—CYP2B6—renal system—muscle cancer	0.000311	0.00703	CbGeAlD
Diclofenac—ABCC4—testis—muscle cancer	0.000309	0.00698	CbGeAlD
Diclofenac—ABCC1—vagina—muscle cancer	0.000295	0.00667	CbGeAlD
Diclofenac—PTGS1—smooth muscle tissue—muscle cancer	0.000292	0.0066	CbGeAlD
Diclofenac—CYP2E1—renal system—muscle cancer	0.000292	0.0066	CbGeAlD
Diclofenac—CYP2C19—vagina—muscle cancer	0.000288	0.0065	CbGeAlD
Diclofenac—CYP1A1—cardiac atrium—muscle cancer	0.000287	0.00648	CbGeAlD
Diclofenac—PTGS1—renal system—muscle cancer	0.000281	0.00636	CbGeAlD
Diclofenac—PTGS2—smooth muscle tissue—muscle cancer	0.000279	0.00631	CbGeAlD
Diclofenac—PTGS2—renal system—muscle cancer	0.000269	0.00608	CbGeAlD
Diclofenac—ABCC1—testis—muscle cancer	0.000263	0.00595	CbGeAlD
Diclofenac—PTGS1—cardiac atrium—muscle cancer	0.000252	0.00569	CbGeAlD
Diclofenac—CYP2C8—vagina—muscle cancer	0.000251	0.00568	CbGeAlD
Diclofenac—CYP3A4—renal system—muscle cancer	0.000235	0.00531	CbGeAlD
Diclofenac—CYP1A1—vagina—muscle cancer	0.000232	0.00524	CbGeAlD
Diclofenac—CYP2E1—tendon—muscle cancer	0.000228	0.00515	CbGeAlD
Diclofenac—CYP2B6—vagina—muscle cancer	0.000225	0.00509	CbGeAlD
Diclofenac—CYP2C8—testis—muscle cancer	0.000224	0.00507	CbGeAlD
Diclofenac—ABCB1—embryo—muscle cancer	0.00022	0.00497	CbGeAlD
Diclofenac—PTGS1—tendon—muscle cancer	0.00022	0.00496	CbGeAlD
Diclofenac—CYP1A1—head—muscle cancer	0.000214	0.00484	CbGeAlD
Diclofenac—PTGS2—tendon—muscle cancer	0.00021	0.00474	CbGeAlD
Diclofenac—CYP2B6—head—muscle cancer	0.000208	0.0047	CbGeAlD
Diclofenac—PTGS1—vagina—muscle cancer	0.000204	0.0046	CbGeAlD
Diclofenac—PTGS2—bone marrow—muscle cancer	0.000203	0.00459	CbGeAlD
Diclofenac—CYP2B6—testis—muscle cancer	0.000201	0.00454	CbGeAlD
Diclofenac—CYP2E1—head—muscle cancer	0.000195	0.00441	CbGeAlD
Diclofenac—PTGS2—vagina—muscle cancer	0.000195	0.0044	CbGeAlD
Diclofenac—CYP2E1—testis—muscle cancer	0.000189	0.00426	CbGeAlD
Diclofenac—PTGS1—head—muscle cancer	0.000188	0.00425	CbGeAlD
Diclofenac—PTGS1—testis—muscle cancer	0.000182	0.00411	CbGeAlD
Diclofenac—PTGS2—head—muscle cancer	0.00018	0.00407	CbGeAlD
Diclofenac—ABCB1—renal system—muscle cancer	0.000166	0.00376	CbGeAlD
Diclofenac—ABCB1—bone marrow—muscle cancer	0.000126	0.00284	CbGeAlD
Diclofenac—Hyperhidrosis—Etoposide—muscle cancer	0.000122	0.00102	CcSEcCtD
Diclofenac—Abdominal pain upper—Doxorubicin—muscle cancer	0.000122	0.00102	CcSEcCtD
Diclofenac—Photosensitivity reaction—Methotrexate—muscle cancer	0.000121	0.00101	CcSEcCtD
Diclofenac—ABCB1—vagina—muscle cancer	0.00012	0.00272	CbGeAlD
Diclofenac—Anorexia—Etoposide—muscle cancer	0.00012	0.001	CcSEcCtD
Diclofenac—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.00012	0.001	CcSEcCtD
Diclofenac—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.00012	0.001	CcSEcCtD
Diclofenac—Diarrhoea—Dactinomycin—muscle cancer	0.000119	0.000996	CcSEcCtD
Diclofenac—Pneumonia—Methotrexate—muscle cancer	0.000119	0.000995	CcSEcCtD
Diclofenac—Nasopharyngitis—Doxorubicin—muscle cancer	0.000119	0.000994	CcSEcCtD
Diclofenac—Infestation—Methotrexate—muscle cancer	0.000119	0.00099	CcSEcCtD
Diclofenac—Infestation NOS—Methotrexate—muscle cancer	0.000119	0.00099	CcSEcCtD
Diclofenac—Drowsiness—Methotrexate—muscle cancer	0.000119	0.00099	CcSEcCtD
Diclofenac—Depression—Methotrexate—muscle cancer	0.000118	0.000987	CcSEcCtD
Diclofenac—Hypotension—Etoposide—muscle cancer	0.000118	0.000985	CcSEcCtD
Diclofenac—Gastritis—Doxorubicin—muscle cancer	0.000118	0.000984	CcSEcCtD
Diclofenac—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000118	0.000981	CcSEcCtD
Diclofenac—Muscular weakness—Doxorubicin—muscle cancer	0.000118	0.000981	CcSEcCtD
Diclofenac—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000118	0.000981	CcSEcCtD
Diclofenac—Renal failure—Methotrexate—muscle cancer	0.000117	0.000973	CcSEcCtD
Diclofenac—Abdominal distension—Doxorubicin—muscle cancer	0.000116	0.000968	CcSEcCtD
Diclofenac—Stomatitis—Methotrexate—muscle cancer	0.000116	0.000965	CcSEcCtD
Diclofenac—Conjunctivitis—Methotrexate—muscle cancer	0.000115	0.000962	CcSEcCtD
Diclofenac—Influenza—Doxorubicin—muscle cancer	0.000115	0.000961	CcSEcCtD
Diclofenac—Asthma—Doxorubicin—muscle cancer	0.000115	0.000961	CcSEcCtD
Diclofenac—Hypersensitivity—Vincristine—muscle cancer	0.000115	0.000958	CcSEcCtD
Diclofenac—Eosinophilia—Doxorubicin—muscle cancer	0.000114	0.000952	CcSEcCtD
Diclofenac—Sweating—Methotrexate—muscle cancer	0.000114	0.000949	CcSEcCtD
Diclofenac—Paraesthesia—Etoposide—muscle cancer	0.000113	0.000946	CcSEcCtD
Diclofenac—Haematuria—Methotrexate—muscle cancer	0.000113	0.000944	CcSEcCtD
Diclofenac—Pancreatitis—Doxorubicin—muscle cancer	0.000113	0.000942	CcSEcCtD
Diclofenac—Dyspnoea—Etoposide—muscle cancer	0.000113	0.00094	CcSEcCtD
Diclofenac—Somnolence—Etoposide—muscle cancer	0.000112	0.000937	CcSEcCtD
Diclofenac—Angina pectoris—Doxorubicin—muscle cancer	0.000112	0.000936	CcSEcCtD
Diclofenac—Hepatobiliary disease—Methotrexate—muscle cancer	0.000112	0.000936	CcSEcCtD
Diclofenac—Epistaxis—Methotrexate—muscle cancer	0.000112	0.000934	CcSEcCtD
Diclofenac—Asthenia—Vincristine—muscle cancer	0.000112	0.000933	CcSEcCtD
Diclofenac—ABCB1—head—muscle cancer	0.000111	0.00251	CbGeAlD
Diclofenac—Vomiting—Dactinomycin—muscle cancer	0.000111	0.000926	CcSEcCtD
Diclofenac—Bronchitis—Doxorubicin—muscle cancer	0.000111	0.000924	CcSEcCtD
Diclofenac—Agranulocytosis—Methotrexate—muscle cancer	0.000111	0.000924	CcSEcCtD
Diclofenac—Rash—Dactinomycin—muscle cancer	0.00011	0.000918	CcSEcCtD
Diclofenac—Decreased appetite—Etoposide—muscle cancer	0.00011	0.000916	CcSEcCtD
Diclofenac—Pancytopenia—Doxorubicin—muscle cancer	0.000109	0.000913	CcSEcCtD
Diclofenac—Gastrointestinal disorder—Etoposide—muscle cancer	0.000109	0.00091	CcSEcCtD
Diclofenac—Fatigue—Etoposide—muscle cancer	0.000109	0.000909	CcSEcCtD
Diclofenac—Constipation—Etoposide—muscle cancer	0.000108	0.000901	CcSEcCtD
Diclofenac—Pain—Etoposide—muscle cancer	0.000108	0.000901	CcSEcCtD
Diclofenac—Dysuria—Doxorubicin—muscle cancer	0.000108	0.000899	CcSEcCtD
Diclofenac—ABCB1—testis—muscle cancer	0.000107	0.00243	CbGeAlD
Diclofenac—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000107	0.000893	CcSEcCtD
Diclofenac—Haemoglobin—Methotrexate—muscle cancer	0.000107	0.000893	CcSEcCtD
Diclofenac—Diarrhoea—Vincristine—muscle cancer	0.000107	0.00089	CcSEcCtD
Diclofenac—Haemorrhage—Methotrexate—muscle cancer	0.000106	0.000888	CcSEcCtD
Diclofenac—Hepatitis—Methotrexate—muscle cancer	0.000106	0.000888	CcSEcCtD
Diclofenac—Pollakiuria—Doxorubicin—muscle cancer	0.000106	0.000888	CcSEcCtD
Diclofenac—Pharyngitis—Methotrexate—muscle cancer	0.000106	0.000882	CcSEcCtD
Diclofenac—Urinary tract disorder—Methotrexate—muscle cancer	0.000105	0.000877	CcSEcCtD
Diclofenac—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000105	0.000877	CcSEcCtD
Diclofenac—Weight increased—Doxorubicin—muscle cancer	0.000105	0.000875	CcSEcCtD
Diclofenac—Urethral disorder—Methotrexate—muscle cancer	0.000104	0.000871	CcSEcCtD
Diclofenac—Weight decreased—Doxorubicin—muscle cancer	0.000104	0.00087	CcSEcCtD
Diclofenac—Feeling abnormal—Etoposide—muscle cancer	0.000104	0.000868	CcSEcCtD
Diclofenac—Hyperglycaemia—Doxorubicin—muscle cancer	0.000104	0.000867	CcSEcCtD
Diclofenac—Nausea—Dactinomycin—muscle cancer	0.000104	0.000865	CcSEcCtD
Diclofenac—Pneumonia—Doxorubicin—muscle cancer	0.000103	0.000862	CcSEcCtD
Diclofenac—Gastrointestinal pain—Etoposide—muscle cancer	0.000103	0.000862	CcSEcCtD
Diclofenac—Dizziness—Vincristine—muscle cancer	0.000103	0.00086	CcSEcCtD
Diclofenac—Infestation—Doxorubicin—muscle cancer	0.000103	0.000857	CcSEcCtD
Diclofenac—Infestation NOS—Doxorubicin—muscle cancer	0.000103	0.000857	CcSEcCtD
Diclofenac—Drowsiness—Doxorubicin—muscle cancer	0.000103	0.000857	CcSEcCtD
Diclofenac—Visual impairment—Methotrexate—muscle cancer	0.000103	0.000856	CcSEcCtD
Diclofenac—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000102	0.00085	CcSEcCtD
Diclofenac—Renal failure—Doxorubicin—muscle cancer	0.000101	0.000842	CcSEcCtD
Diclofenac—Erythema multiforme—Methotrexate—muscle cancer	0.000101	0.00084	CcSEcCtD
Diclofenac—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000101	0.00084	CcSEcCtD
Diclofenac—Urticaria—Etoposide—muscle cancer	0.0001	0.000837	CcSEcCtD
Diclofenac—Stomatitis—Doxorubicin—muscle cancer	0.0001	0.000835	CcSEcCtD
Diclofenac—Jaundice—Doxorubicin—muscle cancer	0.0001	0.000835	CcSEcCtD
Diclofenac—Abdominal pain—Etoposide—muscle cancer	9.99e-05	0.000833	CcSEcCtD
Diclofenac—Body temperature increased—Etoposide—muscle cancer	9.99e-05	0.000833	CcSEcCtD
Diclofenac—Urinary tract infection—Doxorubicin—muscle cancer	9.98e-05	0.000833	CcSEcCtD
Diclofenac—Conjunctivitis—Doxorubicin—muscle cancer	9.98e-05	0.000833	CcSEcCtD
Diclofenac—Eye disorder—Methotrexate—muscle cancer	9.95e-05	0.00083	CcSEcCtD
Diclofenac—Tinnitus—Methotrexate—muscle cancer	9.93e-05	0.000828	CcSEcCtD
Diclofenac—Vomiting—Vincristine—muscle cancer	9.91e-05	0.000827	CcSEcCtD
Diclofenac—Cardiac disorder—Methotrexate—muscle cancer	9.88e-05	0.000825	CcSEcCtD
Diclofenac—Sweating—Doxorubicin—muscle cancer	9.85e-05	0.000822	CcSEcCtD
Diclofenac—Rash—Vincristine—muscle cancer	9.83e-05	0.00082	CcSEcCtD
Diclofenac—Dermatitis—Vincristine—muscle cancer	9.82e-05	0.00082	CcSEcCtD
Diclofenac—Haematuria—Doxorubicin—muscle cancer	9.79e-05	0.000817	CcSEcCtD
Diclofenac—Headache—Vincristine—muscle cancer	9.77e-05	0.000815	CcSEcCtD
Diclofenac—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	9.72e-05	0.00458	CbGpPWpGaD
Diclofenac—Hepatobiliary disease—Doxorubicin—muscle cancer	9.71e-05	0.000811	CcSEcCtD
Diclofenac—Epistaxis—Doxorubicin—muscle cancer	9.69e-05	0.000808	CcSEcCtD
Diclofenac—SCN4A—Developmental Biology—MYOD1—muscle cancer	9.68e-05	0.00456	CbGpPWpGaD
Diclofenac—Angiopathy—Methotrexate—muscle cancer	9.66e-05	0.000806	CcSEcCtD
Diclofenac—Sinusitis—Doxorubicin—muscle cancer	9.64e-05	0.000804	CcSEcCtD
Diclofenac—Immune system disorder—Methotrexate—muscle cancer	9.62e-05	0.000803	CcSEcCtD
Diclofenac—Mediastinal disorder—Methotrexate—muscle cancer	9.6e-05	0.000801	CcSEcCtD
Diclofenac—Agranulocytosis—Doxorubicin—muscle cancer	9.59e-05	0.0008	CcSEcCtD
Diclofenac—Chills—Methotrexate—muscle cancer	9.56e-05	0.000797	CcSEcCtD
Diclofenac—PTGS2—S1P1 pathway—VEGFA—muscle cancer	9.48e-05	0.00447	CbGpPWpGaD
Diclofenac—Alopecia—Methotrexate—muscle cancer	9.41e-05	0.000785	CcSEcCtD
Diclofenac—Bradycardia—Doxorubicin—muscle cancer	9.39e-05	0.000783	CcSEcCtD
Diclofenac—Mental disorder—Methotrexate—muscle cancer	9.33e-05	0.000778	CcSEcCtD
Diclofenac—Hypersensitivity—Etoposide—muscle cancer	9.31e-05	0.000776	CcSEcCtD
Diclofenac—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—muscle cancer	9.31e-05	0.00438	CbGpPWpGaD
Diclofenac—Malnutrition—Methotrexate—muscle cancer	9.27e-05	0.000773	CcSEcCtD
Diclofenac—Erythema—Methotrexate—muscle cancer	9.27e-05	0.000773	CcSEcCtD
Diclofenac—Haemoglobin—Doxorubicin—muscle cancer	9.27e-05	0.000773	CcSEcCtD
Diclofenac—Nausea—Vincristine—muscle cancer	9.26e-05	0.000773	CcSEcCtD
Diclofenac—Rhinitis—Doxorubicin—muscle cancer	9.24e-05	0.000771	CcSEcCtD
Diclofenac—Haemorrhage—Doxorubicin—muscle cancer	9.22e-05	0.000769	CcSEcCtD
Diclofenac—Hepatitis—Doxorubicin—muscle cancer	9.22e-05	0.000769	CcSEcCtD
Diclofenac—Hypoaesthesia—Doxorubicin—muscle cancer	9.18e-05	0.000765	CcSEcCtD
Diclofenac—Pharyngitis—Doxorubicin—muscle cancer	9.15e-05	0.000764	CcSEcCtD
Diclofenac—Urinary tract disorder—Doxorubicin—muscle cancer	9.11e-05	0.00076	CcSEcCtD
Diclofenac—Oedema peripheral—Doxorubicin—muscle cancer	9.08e-05	0.000758	CcSEcCtD
Diclofenac—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	9.08e-05	0.00428	CbGpPWpGaD
Diclofenac—Dysgeusia—Methotrexate—muscle cancer	9.08e-05	0.000757	CcSEcCtD
Diclofenac—Asthenia—Etoposide—muscle cancer	9.06e-05	0.000756	CcSEcCtD
Diclofenac—Urethral disorder—Doxorubicin—muscle cancer	9.04e-05	0.000754	CcSEcCtD
Diclofenac—Back pain—Methotrexate—muscle cancer	8.97e-05	0.000748	CcSEcCtD
Diclofenac—Pruritus—Etoposide—muscle cancer	8.94e-05	0.000746	CcSEcCtD
Diclofenac—Visual impairment—Doxorubicin—muscle cancer	8.89e-05	0.000741	CcSEcCtD
Diclofenac—SCN4A—Developmental Biology—MED12—muscle cancer	8.85e-05	0.00417	CbGpPWpGaD
Diclofenac—CXCL8—Glucocorticoid receptor regulatory network—MDM2—muscle cancer	8.85e-05	0.00417	CbGpPWpGaD
Diclofenac—Vision blurred—Methotrexate—muscle cancer	8.74e-05	0.000729	CcSEcCtD
Diclofenac—CXCL8—Cellular responses to stress—HMGA1—muscle cancer	8.74e-05	0.00412	CbGpPWpGaD
Diclofenac—Erythema multiforme—Doxorubicin—muscle cancer	8.72e-05	0.000727	CcSEcCtD
Diclofenac—Diarrhoea—Etoposide—muscle cancer	8.64e-05	0.000721	CcSEcCtD
Diclofenac—Eye disorder—Doxorubicin—muscle cancer	8.62e-05	0.000719	CcSEcCtD
Diclofenac—Ill-defined disorder—Methotrexate—muscle cancer	8.6e-05	0.000718	CcSEcCtD
Diclofenac—Tinnitus—Doxorubicin—muscle cancer	8.6e-05	0.000717	CcSEcCtD
Diclofenac—Anaemia—Methotrexate—muscle cancer	8.57e-05	0.000715	CcSEcCtD
Diclofenac—Flushing—Doxorubicin—muscle cancer	8.56e-05	0.000714	CcSEcCtD
Diclofenac—Cardiac disorder—Doxorubicin—muscle cancer	8.56e-05	0.000714	CcSEcCtD
Diclofenac—CXCL8—G alpha (i) signalling events—CNR1—muscle cancer	8.44e-05	0.00398	CbGpPWpGaD
Diclofenac—CYP1A2—Melatonin metabolism and effects—FOXO1—muscle cancer	8.4e-05	0.00396	CbGpPWpGaD
Diclofenac—Angiopathy—Doxorubicin—muscle cancer	8.37e-05	0.000698	CcSEcCtD
Diclofenac—Malaise—Methotrexate—muscle cancer	8.36e-05	0.000697	CcSEcCtD
Diclofenac—Dizziness—Etoposide—muscle cancer	8.35e-05	0.000697	CcSEcCtD
Diclofenac—Immune system disorder—Doxorubicin—muscle cancer	8.33e-05	0.000695	CcSEcCtD
Diclofenac—Vertigo—Methotrexate—muscle cancer	8.33e-05	0.000695	CcSEcCtD
Diclofenac—Mediastinal disorder—Doxorubicin—muscle cancer	8.31e-05	0.000693	CcSEcCtD
Diclofenac—Leukopenia—Methotrexate—muscle cancer	8.3e-05	0.000692	CcSEcCtD
Diclofenac—Chills—Doxorubicin—muscle cancer	8.27e-05	0.00069	CcSEcCtD
Diclofenac—ABCC1—Arachidonic acid metabolism—PTGS2—muscle cancer	8.27e-05	0.0039	CbGpPWpGaD
Diclofenac—CYP1A1—PPARA activates gene expression—MED12—muscle cancer	8.26e-05	0.00389	CbGpPWpGaD
Diclofenac—Arrhythmia—Doxorubicin—muscle cancer	8.24e-05	0.000687	CcSEcCtD
Diclofenac—ABCC4—Fluoropyrimidine Activity—TP53—muscle cancer	8.24e-05	0.00388	CbGpPWpGaD
Diclofenac—Alopecia—Doxorubicin—muscle cancer	8.15e-05	0.00068	CcSEcCtD
Diclofenac—Cough—Methotrexate—muscle cancer	8.09e-05	0.000675	CcSEcCtD
Diclofenac—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—MED12—muscle cancer	8.08e-05	0.00381	CbGpPWpGaD
Diclofenac—Mental disorder—Doxorubicin—muscle cancer	8.08e-05	0.000674	CcSEcCtD
Diclofenac—Convulsion—Methotrexate—muscle cancer	8.03e-05	0.00067	CcSEcCtD
Diclofenac—Vomiting—Etoposide—muscle cancer	8.03e-05	0.00067	CcSEcCtD
Diclofenac—Erythema—Doxorubicin—muscle cancer	8.03e-05	0.00067	CcSEcCtD
Diclofenac—Malnutrition—Doxorubicin—muscle cancer	8.03e-05	0.00067	CcSEcCtD
Diclofenac—Rash—Etoposide—muscle cancer	7.96e-05	0.000664	CcSEcCtD
Diclofenac—Dermatitis—Etoposide—muscle cancer	7.96e-05	0.000664	CcSEcCtD
Diclofenac—Headache—Etoposide—muscle cancer	7.91e-05	0.00066	CcSEcCtD
Diclofenac—Flatulence—Doxorubicin—muscle cancer	7.91e-05	0.00066	CcSEcCtD
Diclofenac—Chest pain—Methotrexate—muscle cancer	7.89e-05	0.000658	CcSEcCtD
Diclofenac—Arthralgia—Methotrexate—muscle cancer	7.89e-05	0.000658	CcSEcCtD
Diclofenac—Myalgia—Methotrexate—muscle cancer	7.89e-05	0.000658	CcSEcCtD
Diclofenac—Tension—Doxorubicin—muscle cancer	7.88e-05	0.000657	CcSEcCtD
Diclofenac—Dysgeusia—Doxorubicin—muscle cancer	7.86e-05	0.000656	CcSEcCtD
Diclofenac—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	7.84e-05	0.000654	CcSEcCtD
Diclofenac—Discomfort—Methotrexate—muscle cancer	7.8e-05	0.000651	CcSEcCtD
Diclofenac—Nervousness—Doxorubicin—muscle cancer	7.8e-05	0.00065	CcSEcCtD
Diclofenac—PLA2G2A—Metabolism—FH—muscle cancer	7.79e-05	0.00367	CbGpPWpGaD
Diclofenac—Back pain—Doxorubicin—muscle cancer	7.76e-05	0.000648	CcSEcCtD
Diclofenac—Muscle spasms—Doxorubicin—muscle cancer	7.72e-05	0.000644	CcSEcCtD
Diclofenac—Confusional state—Methotrexate—muscle cancer	7.63e-05	0.000636	CcSEcCtD
Diclofenac—Anaphylactic shock—Methotrexate—muscle cancer	7.57e-05	0.000631	CcSEcCtD
Diclofenac—Vision blurred—Doxorubicin—muscle cancer	7.57e-05	0.000631	CcSEcCtD
Diclofenac—Infection—Methotrexate—muscle cancer	7.52e-05	0.000627	CcSEcCtD
Diclofenac—Nausea—Etoposide—muscle cancer	7.5e-05	0.000626	CcSEcCtD
Diclofenac—CXCL8—Senescence and Autophagy in Cancer—CDKN2A—muscle cancer	7.49e-05	0.00353	CbGpPWpGaD
Diclofenac—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—CDKN2A—muscle cancer	7.49e-05	0.00353	CbGpPWpGaD
Diclofenac—Ill-defined disorder—Doxorubicin—muscle cancer	7.45e-05	0.000621	CcSEcCtD
Diclofenac—Nervous system disorder—Methotrexate—muscle cancer	7.42e-05	0.000619	CcSEcCtD
Diclofenac—Anaemia—Doxorubicin—muscle cancer	7.42e-05	0.000619	CcSEcCtD
Diclofenac—Thrombocytopenia—Methotrexate—muscle cancer	7.41e-05	0.000618	CcSEcCtD
Diclofenac—Agitation—Doxorubicin—muscle cancer	7.38e-05	0.000615	CcSEcCtD
Diclofenac—Skin disorder—Methotrexate—muscle cancer	7.35e-05	0.000613	CcSEcCtD
Diclofenac—Hyperhidrosis—Methotrexate—muscle cancer	7.31e-05	0.00061	CcSEcCtD
Diclofenac—CXCL8—Senescence and Autophagy in Cancer—MDM2—muscle cancer	7.26e-05	0.00342	CbGpPWpGaD
Diclofenac—ALOX5—Metabolism of lipids and lipoproteins—MED12—muscle cancer	7.26e-05	0.00342	CbGpPWpGaD
Diclofenac—Malaise—Doxorubicin—muscle cancer	7.24e-05	0.000604	CcSEcCtD
Diclofenac—Vertigo—Doxorubicin—muscle cancer	7.21e-05	0.000602	CcSEcCtD
Diclofenac—Anorexia—Methotrexate—muscle cancer	7.21e-05	0.000602	CcSEcCtD
Diclofenac—Syncope—Doxorubicin—muscle cancer	7.2e-05	0.000601	CcSEcCtD
Diclofenac—Leukopenia—Doxorubicin—muscle cancer	7.19e-05	0.000599	CcSEcCtD
Diclofenac—Palpitations—Doxorubicin—muscle cancer	7.09e-05	0.000592	CcSEcCtD
Diclofenac—Hypotension—Methotrexate—muscle cancer	7.07e-05	0.00059	CcSEcCtD
Diclofenac—Loss of consciousness—Doxorubicin—muscle cancer	7.06e-05	0.000589	CcSEcCtD
Diclofenac—Cough—Doxorubicin—muscle cancer	7e-05	0.000584	CcSEcCtD
Diclofenac—PTGS1—Arachidonic acid metabolism—PTGS2—muscle cancer	6.99e-05	0.0033	CbGpPWpGaD
Diclofenac—Convulsion—Doxorubicin—muscle cancer	6.96e-05	0.00058	CcSEcCtD
Diclofenac—TTR—Signaling Pathways—KIDINS220—muscle cancer	6.95e-05	0.00328	CbGpPWpGaD
Diclofenac—Hypertension—Doxorubicin—muscle cancer	6.93e-05	0.000578	CcSEcCtD
Diclofenac—CXCL8—Allograft Rejection—VEGFA—muscle cancer	6.92e-05	0.00326	CbGpPWpGaD
Diclofenac—Musculoskeletal discomfort—Methotrexate—muscle cancer	6.89e-05	0.000575	CcSEcCtD
Diclofenac—CXCR1—Signaling by GPCR—PTCH1—muscle cancer	6.89e-05	0.00324	CbGpPWpGaD
Diclofenac—Insomnia—Methotrexate—muscle cancer	6.84e-05	0.000571	CcSEcCtD
Diclofenac—Myalgia—Doxorubicin—muscle cancer	6.83e-05	0.00057	CcSEcCtD
Diclofenac—Chest pain—Doxorubicin—muscle cancer	6.83e-05	0.00057	CcSEcCtD
Diclofenac—Arthralgia—Doxorubicin—muscle cancer	6.83e-05	0.00057	CcSEcCtD
Diclofenac—Anxiety—Doxorubicin—muscle cancer	6.81e-05	0.000568	CcSEcCtD
Diclofenac—Paraesthesia—Methotrexate—muscle cancer	6.79e-05	0.000567	CcSEcCtD
Diclofenac—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	6.79e-05	0.000566	CcSEcCtD
Diclofenac—Discomfort—Doxorubicin—muscle cancer	6.75e-05	0.000563	CcSEcCtD
Diclofenac—Dyspnoea—Methotrexate—muscle cancer	6.75e-05	0.000563	CcSEcCtD
Diclofenac—Somnolence—Methotrexate—muscle cancer	6.73e-05	0.000561	CcSEcCtD
Diclofenac—CXCL8—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	6.71e-05	0.00316	CbGpPWpGaD
Diclofenac—Dry mouth—Doxorubicin—muscle cancer	6.68e-05	0.000558	CcSEcCtD
Diclofenac—Dyspepsia—Methotrexate—muscle cancer	6.66e-05	0.000556	CcSEcCtD
Diclofenac—Confusional state—Doxorubicin—muscle cancer	6.61e-05	0.000551	CcSEcCtD
Diclofenac—PLA2G2A—Spinal Cord Injury—TP53—muscle cancer	6.58e-05	0.0031	CbGpPWpGaD
Diclofenac—Decreased appetite—Methotrexate—muscle cancer	6.58e-05	0.000549	CcSEcCtD
Diclofenac—Anaphylactic shock—Doxorubicin—muscle cancer	6.55e-05	0.000547	CcSEcCtD
Diclofenac—Oedema—Doxorubicin—muscle cancer	6.55e-05	0.000547	CcSEcCtD
Diclofenac—Gastrointestinal disorder—Methotrexate—muscle cancer	6.53e-05	0.000545	CcSEcCtD
Diclofenac—Fatigue—Methotrexate—muscle cancer	6.52e-05	0.000544	CcSEcCtD
Diclofenac—Infection—Doxorubicin—muscle cancer	6.51e-05	0.000543	CcSEcCtD
Diclofenac—Pain—Methotrexate—muscle cancer	6.47e-05	0.00054	CcSEcCtD
Diclofenac—Shock—Doxorubicin—muscle cancer	6.45e-05	0.000538	CcSEcCtD
Diclofenac—Nervous system disorder—Doxorubicin—muscle cancer	6.42e-05	0.000536	CcSEcCtD
Diclofenac—Thrombocytopenia—Doxorubicin—muscle cancer	6.41e-05	0.000535	CcSEcCtD
Diclofenac—KCNQ2—Developmental Biology—FOXO1—muscle cancer	6.41e-05	0.00302	CbGpPWpGaD
Diclofenac—KCNQ3—Developmental Biology—FOXO1—muscle cancer	6.41e-05	0.00302	CbGpPWpGaD
Diclofenac—CXCR1—GPCR downstream signaling—CNR1—muscle cancer	6.4e-05	0.00302	CbGpPWpGaD
Diclofenac—Tachycardia—Doxorubicin—muscle cancer	6.39e-05	0.000533	CcSEcCtD
Diclofenac—CXCL8—Spinal Cord Injury—PTGS2—muscle cancer	6.38e-05	0.003	CbGpPWpGaD
Diclofenac—Skin disorder—Doxorubicin—muscle cancer	6.36e-05	0.000531	CcSEcCtD
Diclofenac—Hyperhidrosis—Doxorubicin—muscle cancer	6.33e-05	0.000528	CcSEcCtD
Diclofenac—Anorexia—Doxorubicin—muscle cancer	6.24e-05	0.000521	CcSEcCtD
Diclofenac—Feeling abnormal—Methotrexate—muscle cancer	6.23e-05	0.00052	CcSEcCtD
Diclofenac—Gastrointestinal pain—Methotrexate—muscle cancer	6.19e-05	0.000516	CcSEcCtD
Diclofenac—Hypotension—Doxorubicin—muscle cancer	6.12e-05	0.000511	CcSEcCtD
Diclofenac—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	6.08e-05	0.00287	CbGpPWpGaD
Diclofenac—KCNQ3—Neuronal System—MDM2—muscle cancer	6.08e-05	0.00286	CbGpPWpGaD
Diclofenac—KCNQ2—Neuronal System—MDM2—muscle cancer	6.08e-05	0.00286	CbGpPWpGaD
Diclofenac—CXCL8—GPCR ligand binding—PTCH1—muscle cancer	6.06e-05	0.00285	CbGpPWpGaD
Diclofenac—ABCC4—Hemostasis—ANGPT2—muscle cancer	6.02e-05	0.00284	CbGpPWpGaD
Diclofenac—Urticaria—Methotrexate—muscle cancer	6.01e-05	0.000501	CcSEcCtD
Diclofenac—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	5.99e-05	0.00282	CbGpPWpGaD
Diclofenac—Abdominal pain—Methotrexate—muscle cancer	5.98e-05	0.000499	CcSEcCtD
Diclofenac—Body temperature increased—Methotrexate—muscle cancer	5.98e-05	0.000499	CcSEcCtD
Diclofenac—Musculoskeletal discomfort—Doxorubicin—muscle cancer	5.97e-05	0.000498	CcSEcCtD
Diclofenac—Insomnia—Doxorubicin—muscle cancer	5.93e-05	0.000494	CcSEcCtD
Diclofenac—Paraesthesia—Doxorubicin—muscle cancer	5.88e-05	0.000491	CcSEcCtD
Diclofenac—Dyspnoea—Doxorubicin—muscle cancer	5.84e-05	0.000487	CcSEcCtD
Diclofenac—Somnolence—Doxorubicin—muscle cancer	5.82e-05	0.000486	CcSEcCtD
Diclofenac—CXCR1—Signaling by GPCR—CNR1—muscle cancer	5.81e-05	0.00274	CbGpPWpGaD
Diclofenac—CYP2E1—Tryptophan metabolism—MDM2—muscle cancer	5.79e-05	0.00273	CbGpPWpGaD
Diclofenac—ALB—Platelet degranulation—IGF2—muscle cancer	5.79e-05	0.00273	CbGpPWpGaD
Diclofenac—Dyspepsia—Doxorubicin—muscle cancer	5.77e-05	0.000481	CcSEcCtD
Diclofenac—CXCL8—AP-1 transcription factor network—TP53—muscle cancer	5.76e-05	0.00272	CbGpPWpGaD
Diclofenac—ALOX5—Metabolism—FH—muscle cancer	5.72e-05	0.0027	CbGpPWpGaD
Diclofenac—Decreased appetite—Doxorubicin—muscle cancer	5.7e-05	0.000475	CcSEcCtD
Diclofenac—ABCC4—Platelet activation, signaling and aggregation—IGF2—muscle cancer	5.68e-05	0.00268	CbGpPWpGaD
Diclofenac—Gastrointestinal disorder—Doxorubicin—muscle cancer	5.66e-05	0.000472	CcSEcCtD
Diclofenac—Fatigue—Doxorubicin—muscle cancer	5.65e-05	0.000471	CcSEcCtD
Diclofenac—Constipation—Doxorubicin—muscle cancer	5.6e-05	0.000467	CcSEcCtD
Diclofenac—Pain—Doxorubicin—muscle cancer	5.6e-05	0.000467	CcSEcCtD
Diclofenac—Hypersensitivity—Methotrexate—muscle cancer	5.57e-05	0.000465	CcSEcCtD
Diclofenac—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	5.57e-05	0.00262	CbGpPWpGaD
Diclofenac—ALB—Response to elevated platelet cytosolic Ca2+—IGF2—muscle cancer	5.52e-05	0.0026	CbGpPWpGaD
Diclofenac—CYP1A1—Tryptophan metabolism—MDM2—muscle cancer	5.46e-05	0.00257	CbGpPWpGaD
Diclofenac—Asthenia—Methotrexate—muscle cancer	5.43e-05	0.000453	CcSEcCtD
Diclofenac—Feeling abnormal—Doxorubicin—muscle cancer	5.4e-05	0.00045	CcSEcCtD
Diclofenac—ABCC4—Platelet degranulation—VEGFA—muscle cancer	5.37e-05	0.00253	CbGpPWpGaD
Diclofenac—Gastrointestinal pain—Doxorubicin—muscle cancer	5.36e-05	0.000447	CcSEcCtD
Diclofenac—Pruritus—Methotrexate—muscle cancer	5.35e-05	0.000447	CcSEcCtD
Diclofenac—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	5.31e-05	0.0025	CbGpPWpGaD
Diclofenac—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	5.27e-05	0.00248	CbGpPWpGaD
Diclofenac—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	5.27e-05	0.00248	CbGpPWpGaD
Diclofenac—Urticaria—Doxorubicin—muscle cancer	5.2e-05	0.000434	CcSEcCtD
Diclofenac—Body temperature increased—Doxorubicin—muscle cancer	5.18e-05	0.000432	CcSEcCtD
Diclofenac—Abdominal pain—Doxorubicin—muscle cancer	5.18e-05	0.000432	CcSEcCtD
Diclofenac—Diarrhoea—Methotrexate—muscle cancer	5.18e-05	0.000432	CcSEcCtD
Diclofenac—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	5.11e-05	0.00241	CbGpPWpGaD
Diclofenac—CXCL8—GPCR ligand binding—CNR1—muscle cancer	5.11e-05	0.00241	CbGpPWpGaD
Diclofenac—CXCL8—Glucocorticoid receptor regulatory network—TP53—muscle cancer	5.08e-05	0.00239	CbGpPWpGaD
Diclofenac—Dizziness—Methotrexate—muscle cancer	5e-05	0.000417	CcSEcCtD
Diclofenac—CYP1A1—Arachidonic acid metabolism—PTGS2—muscle cancer	4.93e-05	0.00232	CbGpPWpGaD
Diclofenac—SCN4A—Developmental Biology—FOXO1—muscle cancer	4.86e-05	0.00229	CbGpPWpGaD
Diclofenac—PTGS2—C-MYB transcription factor network—KIT—muscle cancer	4.83e-05	0.00228	CbGpPWpGaD
Diclofenac—Hypersensitivity—Doxorubicin—muscle cancer	4.83e-05	0.000403	CcSEcCtD
Diclofenac—Vomiting—Methotrexate—muscle cancer	4.81e-05	0.000401	CcSEcCtD
Diclofenac—Rash—Methotrexate—muscle cancer	4.77e-05	0.000398	CcSEcCtD
Diclofenac—Dermatitis—Methotrexate—muscle cancer	4.77e-05	0.000398	CcSEcCtD
Diclofenac—Headache—Methotrexate—muscle cancer	4.74e-05	0.000395	CcSEcCtD
Diclofenac—CXCL8—Cellular Senescence—CDKN2A—muscle cancer	4.74e-05	0.00223	CbGpPWpGaD
Diclofenac—Asthenia—Doxorubicin—muscle cancer	4.7e-05	0.000392	CcSEcCtD
Diclofenac—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	4.67e-05	0.0022	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—KIDINS220—muscle cancer	4.66e-05	0.0022	CbGpPWpGaD
Diclofenac—Pruritus—Doxorubicin—muscle cancer	4.64e-05	0.000387	CcSEcCtD
Diclofenac—CXCL8—Cellular Senescence—MDM2—muscle cancer	4.6e-05	0.00217	CbGpPWpGaD
Diclofenac—CYP2C8—Arachidonic acid metabolism—PTGS2—muscle cancer	4.52e-05	0.00213	CbGpPWpGaD
Diclofenac—Nausea—Methotrexate—muscle cancer	4.49e-05	0.000375	CcSEcCtD
Diclofenac—Diarrhoea—Doxorubicin—muscle cancer	4.48e-05	0.000374	CcSEcCtD
Diclofenac—PTGS1—Selenium Micronutrient Network—PTGS2—muscle cancer	4.45e-05	0.0021	CbGpPWpGaD
Diclofenac—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	4.45e-05	0.0021	CbGpPWpGaD
Diclofenac—PLA2G2A—Metabolism—MED12—muscle cancer	4.4e-05	0.00208	CbGpPWpGaD
Diclofenac—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—muscle cancer	4.39e-05	0.00207	CbGpPWpGaD
Diclofenac—Dizziness—Doxorubicin—muscle cancer	4.33e-05	0.000361	CcSEcCtD
Diclofenac—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	4.31e-05	0.00203	CbGpPWpGaD
Diclofenac—CXCL8—Senescence and Autophagy in Cancer—TP53—muscle cancer	4.17e-05	0.00196	CbGpPWpGaD
Diclofenac—Vomiting—Doxorubicin—muscle cancer	4.17e-05	0.000348	CcSEcCtD
Diclofenac—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	4.15e-05	0.00195	CbGpPWpGaD
Diclofenac—Rash—Doxorubicin—muscle cancer	4.13e-05	0.000345	CcSEcCtD
Diclofenac—Dermatitis—Doxorubicin—muscle cancer	4.13e-05	0.000344	CcSEcCtD
Diclofenac—TTR—Disease—ENO2—muscle cancer	4.12e-05	0.00194	CbGpPWpGaD
Diclofenac—Headache—Doxorubicin—muscle cancer	4.1e-05	0.000342	CcSEcCtD
Diclofenac—KCNQ2—Axon guidance—VEGFA—muscle cancer	4.09e-05	0.00193	CbGpPWpGaD
Diclofenac—KCNQ3—Axon guidance—VEGFA—muscle cancer	4.09e-05	0.00193	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—PTCH1—muscle cancer	4.07e-05	0.00192	CbGpPWpGaD
Diclofenac—CYP2C19—Arachidonic acid metabolism—PTGS2—muscle cancer	4.03e-05	0.0019	CbGpPWpGaD
Diclofenac—CXCL8—SIDS Susceptibility Pathways—VEGFA—muscle cancer	4.02e-05	0.00189	CbGpPWpGaD
Diclofenac—PLA2G2A—Metabolism—ENO2—muscle cancer	4.02e-05	0.00189	CbGpPWpGaD
Diclofenac—PTGS2—C-MYB transcription factor network—CDKN2A—muscle cancer	3.92e-05	0.00185	CbGpPWpGaD
Diclofenac—Nausea—Doxorubicin—muscle cancer	3.89e-05	0.000325	CcSEcCtD
Diclofenac—CYP2C18—Metabolism—FH—muscle cancer	3.85e-05	0.00181	CbGpPWpGaD
Diclofenac—CXCL8—Spinal Cord Injury—TP53—muscle cancer	3.79e-05	0.00179	CbGpPWpGaD
Diclofenac—TTR—Disease—HMGA1—muscle cancer	3.75e-05	0.00177	CbGpPWpGaD
Diclofenac—UGT2B7—Metabolism—FH—muscle cancer	3.74e-05	0.00176	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	3.72e-05	0.00175	CbGpPWpGaD
Diclofenac—CYP2C9—Arachidonic acid metabolism—PTGS2—muscle cancer	3.68e-05	0.00173	CbGpPWpGaD
Diclofenac—CXCL8—Cellular responses to stress—CDKN2A—muscle cancer	3.58e-05	0.00169	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—FOXO4—muscle cancer	3.5e-05	0.00165	CbGpPWpGaD
Diclofenac—CYP1A2—Tryptophan metabolism—MDM2—muscle cancer	3.48e-05	0.00164	CbGpPWpGaD
Diclofenac—CXCL8—Cellular responses to stress—MDM2—muscle cancer	3.47e-05	0.00164	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—CNR1—muscle cancer	3.43e-05	0.00162	CbGpPWpGaD
Diclofenac—TTR—Disease—FOXO4—muscle cancer	3.36e-05	0.00158	CbGpPWpGaD
Diclofenac—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	3.36e-05	0.00158	CbGpPWpGaD
Diclofenac—ALOX5—Metabolism—MED12—muscle cancer	3.23e-05	0.00152	CbGpPWpGaD
Diclofenac—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	3.15e-05	0.00149	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	3.15e-05	0.00148	CbGpPWpGaD
Diclofenac—CYP1A2—Arachidonic acid metabolism—PTGS2—muscle cancer	3.14e-05	0.00148	CbGpPWpGaD
Diclofenac—PLA2G2A—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.14e-05	0.00148	CbGpPWpGaD
Diclofenac—CXCL8—Signaling by GPCR—PTCH1—muscle cancer	3.11e-05	0.00146	CbGpPWpGaD
Diclofenac—SCN4A—Axon guidance—VEGFA—muscle cancer	3.1e-05	0.00146	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—FH—muscle cancer	3.04e-05	0.00143	CbGpPWpGaD
Diclofenac—ALOX5—Metabolism—ENO2—muscle cancer	2.95e-05	0.00139	CbGpPWpGaD
Diclofenac—CXCL8—Metabolism of proteins—IGF2—muscle cancer	2.94e-05	0.00139	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—FH—muscle cancer	2.93e-05	0.00138	CbGpPWpGaD
Diclofenac—ABCC4—Hemostasis—IGF2—muscle cancer	2.93e-05	0.00138	CbGpPWpGaD
Diclofenac—KCNQ2—Developmental Biology—VEGFA—muscle cancer	2.92e-05	0.00138	CbGpPWpGaD
Diclofenac—KCNQ3—Developmental Biology—VEGFA—muscle cancer	2.92e-05	0.00138	CbGpPWpGaD
Diclofenac—CXCL8—GPCR downstream signaling—CNR1—muscle cancer	2.89e-05	0.00136	CbGpPWpGaD
Diclofenac—ALB—Selenium Micronutrient Network—PTGS2—muscle cancer	2.86e-05	0.00135	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—IGF2—muscle cancer	2.81e-05	0.00132	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—PTCH1—muscle cancer	2.74e-05	0.00129	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—ANGPT2—muscle cancer	2.72e-05	0.00128	CbGpPWpGaD
Diclofenac—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	2.69e-05	0.00127	CbGpPWpGaD
Diclofenac—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	2.65e-05	0.00125	CbGpPWpGaD
Diclofenac—CXCL8—Cellular responses to stress—VEGFA—muscle cancer	2.64e-05	0.00124	CbGpPWpGaD
Diclofenac—CXCL8—Cellular Senescence—TP53—muscle cancer	2.64e-05	0.00124	CbGpPWpGaD
Diclofenac—CXCL8—Signaling by GPCR—CNR1—muscle cancer	2.62e-05	0.00124	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—FOXO1—muscle cancer	2.58e-05	0.00122	CbGpPWpGaD
Diclofenac—ALB—Platelet activation, signaling and aggregation—IGF2—muscle cancer	2.57e-05	0.00121	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.5e-05	0.00118	CbGpPWpGaD
Diclofenac—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	2.48e-05	0.00117	CbGpPWpGaD
Diclofenac—TTR—Disease—FOXO1—muscle cancer	2.48e-05	0.00117	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—FH—muscle cancer	2.48e-05	0.00117	CbGpPWpGaD
Diclofenac—ALB—Platelet degranulation—VEGFA—muscle cancer	2.43e-05	0.00114	CbGpPWpGaD
Diclofenac—ABCC4—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	2.38e-05	0.00112	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—FOXO4—muscle cancer	2.35e-05	0.00111	CbGpPWpGaD
Diclofenac—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	2.31e-05	0.00109	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—CNR1—muscle cancer	2.31e-05	0.00109	CbGpPWpGaD
Diclofenac—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.3e-05	0.00109	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.22e-05	0.00104	CbGpPWpGaD
Diclofenac—SCN4A—Developmental Biology—VEGFA—muscle cancer	2.21e-05	0.00104	CbGpPWpGaD
Diclofenac—CYP2C18—Metabolism—MED12—muscle cancer	2.18e-05	0.00102	CbGpPWpGaD
Diclofenac—ABCB1—Allograft Rejection—VEGFA—muscle cancer	2.15e-05	0.00101	CbGpPWpGaD
Diclofenac—ALB—Folate Metabolism—TP53—muscle cancer	2.14e-05	0.00101	CbGpPWpGaD
Diclofenac—UGT2B7—Metabolism—MED12—muscle cancer	2.12e-05	0.000997	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.03e-05	0.000958	CbGpPWpGaD
Diclofenac—ALB—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.02e-05	0.000953	CbGpPWpGaD
Diclofenac—CXCL8—Cellular responses to stress—TP53—muscle cancer	1.99e-05	0.000939	CbGpPWpGaD
Diclofenac—CYP2C18—Metabolism—ENO2—muscle cancer	1.98e-05	0.000934	CbGpPWpGaD
Diclofenac—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	1.97e-05	0.000929	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—FH—muscle cancer	1.97e-05	0.000928	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—KIT—muscle cancer	1.97e-05	0.000927	CbGpPWpGaD
Diclofenac—UGT2B7—Metabolism—ENO2—muscle cancer	1.93e-05	0.000909	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—FH—muscle cancer	1.89e-05	0.000892	CbGpPWpGaD
Diclofenac—TTR—Disease—KIT—muscle cancer	1.89e-05	0.000891	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—IGF2—muscle cancer	1.89e-05	0.00089	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—FH—muscle cancer	1.85e-05	0.000874	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—PTCH1—muscle cancer	1.84e-05	0.000865	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.81e-05	0.000855	CbGpPWpGaD
Diclofenac—ABCC1—Disease—ENO2—muscle cancer	1.8e-05	0.000851	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—FH—muscle cancer	1.75e-05	0.000824	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—FOXO1—muscle cancer	1.74e-05	0.000819	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—MED12—muscle cancer	1.72e-05	0.00081	CbGpPWpGaD
Diclofenac—PTGS2—Spinal Cord Injury—TP53—muscle cancer	1.66e-05	0.000783	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—MED12—muscle cancer	1.66e-05	0.000781	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.65e-05	0.00078	CbGpPWpGaD
Diclofenac—ABCC1—Disease—HMGA1—muscle cancer	1.64e-05	0.000773	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—FH—muscle cancer	1.6e-05	0.000755	CbGpPWpGaD
Diclofenac—ALB—Metabolism—FH—muscle cancer	1.59e-05	0.000751	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—FOXO4—muscle cancer	1.58e-05	0.000744	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—ENO2—muscle cancer	1.57e-05	0.000739	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—MDM2—muscle cancer	1.55e-05	0.00073	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—CNR1—muscle cancer	1.55e-05	0.00073	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—ENO2—muscle cancer	1.51e-05	0.000712	CbGpPWpGaD
Diclofenac—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.5e-05	0.000705	CbGpPWpGaD
Diclofenac—TTR—Disease—MDM2—muscle cancer	1.49e-05	0.000702	CbGpPWpGaD
Diclofenac—ABCC1—Disease—FOXO4—muscle cancer	1.47e-05	0.000693	CbGpPWpGaD
Diclofenac—TTR—Disease—PTGS2—muscle cancer	1.44e-05	0.000677	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—FH—muscle cancer	1.43e-05	0.000674	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.41e-05	0.000666	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—MED12—muscle cancer	1.4e-05	0.00066	CbGpPWpGaD
Diclofenac—PLA2G2A—Metabolism—PTGS2—muscle cancer	1.4e-05	0.000659	CbGpPWpGaD
Diclofenac—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	1.4e-05	0.000658	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—FH—muscle cancer	1.4e-05	0.000658	CbGpPWpGaD
Diclofenac—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	1.35e-05	0.000635	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—KIT—muscle cancer	1.32e-05	0.000624	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—IGF2—muscle cancer	1.32e-05	0.000624	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—FH—muscle cancer	1.3e-05	0.000615	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—ENO2—muscle cancer	1.28e-05	0.000602	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—IGF2—muscle cancer	1.27e-05	0.000597	CbGpPWpGaD
Diclofenac—ABCC4—Hemostasis—VEGFA—muscle cancer	1.23e-05	0.000578	CbGpPWpGaD
Diclofenac—PTGS2—Disease—ENO2—muscle cancer	1.21e-05	0.000571	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.18e-05	0.000557	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—VEGFA—muscle cancer	1.18e-05	0.000555	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—FOXO1—muscle cancer	1.17e-05	0.000549	CbGpPWpGaD
Diclofenac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.13e-05	0.000533	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—FH—muscle cancer	1.11e-05	0.000525	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—MED12—muscle cancer	1.11e-05	0.000524	CbGpPWpGaD
Diclofenac—PTGS2—Disease—HMGA1—muscle cancer	1.1e-05	0.000519	CbGpPWpGaD
Diclofenac—ABCC1—Disease—FOXO1—muscle cancer	1.09e-05	0.000512	CbGpPWpGaD
Diclofenac—ALB—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	1.08e-05	0.000508	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—MED12—muscle cancer	1.07e-05	0.000504	CbGpPWpGaD
Diclofenac—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.06e-05	0.0005	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—MED12—muscle cancer	1.05e-05	0.000494	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—MDM2—muscle cancer	1.04e-05	0.000492	CbGpPWpGaD
Diclofenac—ALOX5—Metabolism—PTGS2—muscle cancer	1.03e-05	0.000484	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—ENO2—muscle cancer	1.01e-05	0.000478	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	9.99e-06	0.000471	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—MED12—muscle cancer	9.88e-06	0.000465	CbGpPWpGaD
Diclofenac—PTGS2—Disease—FOXO4—muscle cancer	9.87e-06	0.000465	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—ENO2—muscle cancer	9.75e-06	0.000459	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—ENO2—muscle cancer	9.55e-06	0.00045	CbGpPWpGaD
Diclofenac—ABCC4—Hemostasis—TP53—muscle cancer	9.27e-06	0.000437	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—MED12—muscle cancer	9.05e-06	0.000427	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—ENO2—muscle cancer	9e-06	0.000424	CbGpPWpGaD
Diclofenac—ALB—Metabolism—MED12—muscle cancer	9e-06	0.000424	CbGpPWpGaD
Diclofenac—CXCR1—Signaling Pathways—TP53—muscle cancer	8.89e-06	0.000419	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—KIT—muscle cancer	8.88e-06	0.000419	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—FH—muscle cancer	8.6e-06	0.000405	CbGpPWpGaD
Diclofenac—ABCC1—Disease—KIT—muscle cancer	8.28e-06	0.00039	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—ENO2—muscle cancer	8.25e-06	0.000389	CbGpPWpGaD
Diclofenac—ALB—Metabolism—ENO2—muscle cancer	8.21e-06	0.000387	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—MED12—muscle cancer	8.08e-06	0.000381	CbGpPWpGaD
Diclofenac—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	8.02e-06	0.000378	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—VEGFA—muscle cancer	7.92e-06	0.000373	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—MED12—muscle cancer	7.89e-06	0.000372	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—MED12—muscle cancer	7.37e-06	0.000347	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—ENO2—muscle cancer	7.37e-06	0.000347	CbGpPWpGaD
Diclofenac—PTGS2—Disease—FOXO1—muscle cancer	7.29e-06	0.000344	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—ENO2—muscle cancer	7.19e-06	0.000339	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	7.04e-06	0.000332	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—MDM2—muscle cancer	7e-06	0.00033	CbGpPWpGaD
Diclofenac—CYP2C18—Metabolism—PTGS2—muscle cancer	6.91e-06	0.000325	CbGpPWpGaD
Diclofenac—UGT2B7—Metabolism—PTGS2—muscle cancer	6.72e-06	0.000317	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—ENO2—muscle cancer	6.72e-06	0.000317	CbGpPWpGaD
Diclofenac—ABCC1—Disease—MDM2—muscle cancer	6.52e-06	0.000307	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.46e-06	0.000304	CbGpPWpGaD
Diclofenac—ALB—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.42e-06	0.000302	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—MED12—muscle cancer	6.3e-06	0.000297	CbGpPWpGaD
Diclofenac—ABCC1—Disease—PTGS2—muscle cancer	6.29e-06	0.000296	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—TP53—muscle cancer	5.98e-06	0.000282	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.76e-06	0.000272	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—ENO2—muscle cancer	5.74e-06	0.000271	CbGpPWpGaD
Diclofenac—PTGS2—Disease—KIT—muscle cancer	5.56e-06	0.000262	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—VEGFA—muscle cancer	5.55e-06	0.000262	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—PTGS2—muscle cancer	5.46e-06	0.000257	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—VEGFA—muscle cancer	5.31e-06	0.00025	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—PTGS2—muscle cancer	5.26e-06	0.000248	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.25e-06	0.000248	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—MED12—muscle cancer	4.86e-06	0.000229	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	4.49e-06	0.000212	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—PTGS2—muscle cancer	4.45e-06	0.00021	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—ENO2—muscle cancer	4.43e-06	0.000209	CbGpPWpGaD
Diclofenac—PTGS2—Disease—MDM2—muscle cancer	4.38e-06	0.000206	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—TP53—muscle cancer	4.2e-06	0.000198	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—TP53—muscle cancer	4.01e-06	0.000189	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—PTGS2—muscle cancer	3.4e-06	0.00016	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—PTGS2—muscle cancer	3.33e-06	0.000157	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—PTGS2—muscle cancer	3.14e-06	0.000148	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—PTGS2—muscle cancer	2.87e-06	0.000135	CbGpPWpGaD
Diclofenac—ALB—Metabolism—PTGS2—muscle cancer	2.86e-06	0.000135	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—PTGS2—muscle cancer	2.57e-06	0.000121	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—PTGS2—muscle cancer	2.5e-06	0.000118	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—PTGS2—muscle cancer	2.34e-06	0.00011	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—PTGS2—muscle cancer	2e-06	9.42e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—PTGS2—muscle cancer	1.54e-06	7.27e-05	CbGpPWpGaD
